JP6250628B2 - ベンダムスチンの製剤 - Google Patents

ベンダムスチンの製剤 Download PDF

Info

Publication number
JP6250628B2
JP6250628B2 JP2015501813A JP2015501813A JP6250628B2 JP 6250628 B2 JP6250628 B2 JP 6250628B2 JP 2015501813 A JP2015501813 A JP 2015501813A JP 2015501813 A JP2015501813 A JP 2015501813A JP 6250628 B2 JP6250628 B2 JP 6250628B2
Authority
JP
Japan
Prior art keywords
liquid composition
volume
bendamustine
administered
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015501813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510939A (ja
JP2015510939A5 (enExample
Inventor
スンダラム，スリカンス
Original Assignee
イーグル・ファーマシューティカルズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6250628(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イーグル・ファーマシューティカルズ・インコーポレーテッド filed Critical イーグル・ファーマシューティカルズ・インコーポレーテッド
Publication of JP2015510939A publication Critical patent/JP2015510939A/ja
Publication of JP2015510939A5 publication Critical patent/JP2015510939A5/ja
Application granted granted Critical
Publication of JP6250628B2 publication Critical patent/JP6250628B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015501813A 2012-03-20 2013-03-15 ベンダムスチンの製剤 Active JP6250628B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261613173P 2012-03-20 2012-03-20
US61/613,173 2012-03-20
US201261669889P 2012-07-10 2012-07-10
US61/669,889 2012-07-10
PCT/US2013/032289 WO2013142358A1 (en) 2012-03-20 2013-03-15 Formulations of bendamustine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017224298A Division JP6570601B2 (ja) 2012-03-20 2017-11-22 ベンダムスチンの製剤

Publications (3)

Publication Number Publication Date
JP2015510939A JP2015510939A (ja) 2015-04-13
JP2015510939A5 JP2015510939A5 (enExample) 2016-04-14
JP6250628B2 true JP6250628B2 (ja) 2017-12-20

Family

ID=49212372

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2015501813A Active JP6250628B2 (ja) 2012-03-20 2013-03-15 ベンダムスチンの製剤
JP2017224298A Active JP6570601B2 (ja) 2012-03-20 2017-11-22 ベンダムスチンの製剤
JP2019144489A Withdrawn JP2019214592A (ja) 2012-03-20 2019-08-06 ベンダムスチンの製剤
JP2021125009A Active JP7133070B2 (ja) 2012-03-20 2021-07-30 ベンダムスチンの製剤
JP2022105477A Pending JP2022130630A (ja) 2012-03-20 2022-06-30 ベンダムスチンの製剤
JP2022105476A Pending JP2022130629A (ja) 2012-03-20 2022-06-30 ベンダムスチンの製剤
JP2022117843A Pending JP2022141895A (ja) 2012-03-20 2022-07-25 ベンダムスチンの製剤
JP2024008381A Pending JP2024045290A (ja) 2012-03-20 2024-01-24 ベンダムスチンの製剤

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2017224298A Active JP6570601B2 (ja) 2012-03-20 2017-11-22 ベンダムスチンの製剤
JP2019144489A Withdrawn JP2019214592A (ja) 2012-03-20 2019-08-06 ベンダムスチンの製剤
JP2021125009A Active JP7133070B2 (ja) 2012-03-20 2021-07-30 ベンダムスチンの製剤
JP2022105477A Pending JP2022130630A (ja) 2012-03-20 2022-06-30 ベンダムスチンの製剤
JP2022105476A Pending JP2022130629A (ja) 2012-03-20 2022-06-30 ベンダムスチンの製剤
JP2022117843A Pending JP2022141895A (ja) 2012-03-20 2022-07-25 ベンダムスチンの製剤
JP2024008381A Pending JP2024045290A (ja) 2012-03-20 2024-01-24 ベンダムスチンの製剤

Country Status (15)

Country Link
US (19) US9034908B2 (enExample)
EP (2) EP4360621A3 (enExample)
JP (8) JP6250628B2 (enExample)
CN (1) CN104302291A (enExample)
CA (1) CA2867295C (enExample)
DK (1) DK2827862T3 (enExample)
ES (1) ES2972227T3 (enExample)
FI (1) FI2827862T3 (enExample)
HR (1) HRP20240056T1 (enExample)
HU (1) HUE064884T2 (enExample)
PL (1) PL2827862T3 (enExample)
PT (1) PT2827862T (enExample)
RS (1) RS65177B1 (enExample)
SI (1) SI2827862T1 (enExample)
WO (1) WO2013142358A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019214592A (ja) * 2012-03-20 2019-12-19 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3158991T (lt) 2010-01-28 2021-07-12 Eagle Pharmaceuticals, Inc. Bendamustino kompozicijos
DK2827863T3 (en) 2012-03-20 2019-04-23 Eagle Pharmaceuticals Inc LIQUID COMPOSITION FOR USE IN A PROCEDURE FOR TREATING BENDAMUSTIN-RESPONSIVE CONDITIONS OF PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATION
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
AU2014311570C1 (en) 2013-08-27 2018-08-02 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
CN110772480B (zh) * 2016-03-25 2022-05-17 南京百劲企业管理咨询有限公司 苯达莫司汀药剂组合物及应用
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
WO2020035806A1 (en) 2018-08-17 2020-02-20 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
US11992514B2 (en) 2019-05-20 2024-05-28 MAIA Pharmaceuticals, Inc. Ready-to-use bivalirudin compositions
WO2020236150A1 (en) * 2019-05-20 2020-11-26 MAIA Pharmaceuticals, Inc. Ready-to-use bivalirudin compositions
CA3145107A1 (en) * 2020-04-09 2021-10-14 Yue Jing Bendamustine and cyclodextrin composition and use thereof
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (enExample) 1903-10-08 1905-03-16
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
BR9506564A (pt) 1994-01-24 1997-09-02 Procter & Gamble Processo para solubilizar ativos farmacêuticos de dificil solubilidade
EA200000087A1 (ru) 1997-07-01 2000-08-28 Атеродженикс, Инк. Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
KR100627614B1 (ko) 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
AU2001211213A1 (en) 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
AR054094A1 (es) 2004-11-05 2007-06-06 Cephalon Inc Tratamientos de cancer
WO2006054315A1 (en) 2004-11-22 2006-05-26 Venus Remedies Limited Nonaqueous liquid parenteral aceclofenac formulation
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AU2006235183B2 (en) 2005-04-08 2011-02-10 Amylin Pharmaceuticals, Llc Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
CA2659562A1 (en) 2006-08-14 2008-02-21 Eisai R&D Management Co., Ltd. Stable lyophilized preparation
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
US8414909B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
JP5670335B2 (ja) 2008-09-25 2015-02-18 セファロン、インク． ベンダムスチン液体製剤
CA2749101A1 (en) 2009-01-15 2010-07-22 Cephalon, Inc. Novel forms of bendamustine free base
HUE038234T2 (hu) 2009-02-25 2018-10-29 Softkemo Pharma Corp Bendamusztin és ciklopoliszacharid kompozíciók
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
CN102413816A (zh) 2009-04-28 2012-04-11 赛福伦公司 苯达莫司汀的口服制剂
CN101584668A (zh) 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
LT3158991T (lt) * 2010-01-28 2021-07-12 Eagle Pharmaceuticals, Inc. Bendamustino kompozicijos
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2598148A4 (en) 2010-07-28 2014-05-28 Eagle Pharmaceuticals Inc PHARMACEUTICAL COMPOSITIONS WITH PEMETREXED WITH EXTENDED STORAGE STABILITY
EP3712173B1 (en) 2011-12-05 2023-07-12 X-Body, Inc. Pdgf receptor beta binding polypeptides
WO2013112762A1 (en) * 2012-01-24 2013-08-01 Innopharma, Inc. Bendamustine compositions and methods therefore
KR101951319B1 (ko) * 2012-02-07 2019-02-22 삼성전자주식회사 가변 초점 렌즈
US20130210879A1 (en) * 2012-02-14 2013-08-15 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
PT2827862T (pt) * 2012-03-20 2024-03-06 Eagle Pharmaceuticals Inc Formulações de bendamustina
DK2827863T3 (en) * 2012-03-20 2019-04-23 Eagle Pharmaceuticals Inc LIQUID COMPOSITION FOR USE IN A PROCEDURE FOR TREATING BENDAMUSTIN-RESPONSIVE CONDITIONS OF PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATION
US9587397B1 (en) * 2015-09-29 2017-03-07 John Milner McCary, SR. Insulating and support assembly
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019214592A (ja) * 2012-03-20 2019-12-19 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤

Also Published As

Publication number Publication date
JP2022130630A (ja) 2022-09-06
US20230285563A1 (en) 2023-09-14
WO2013142358A1 (en) 2013-09-26
RS65177B1 (sr) 2024-03-29
DK2827862T3 (da) 2024-02-12
EP2827862A4 (en) 2015-11-18
JP2024045290A (ja) 2024-04-02
US9572888B2 (en) 2017-02-21
EP2827862B1 (en) 2023-12-27
JP2018070624A (ja) 2018-05-10
US20160296621A1 (en) 2016-10-13
US20160144035A1 (en) 2016-05-26
FI2827862T3 (fi) 2024-02-13
US9597398B2 (en) 2017-03-21
CA2867295A1 (en) 2013-09-26
JP2015510939A (ja) 2015-04-13
PT2827862T (pt) 2024-03-06
ES2972227T3 (es) 2024-06-11
US20130253025A1 (en) 2013-09-26
US20150250766A1 (en) 2015-09-10
US20140094496A1 (en) 2014-04-03
JP2019214592A (ja) 2019-12-19
US9572887B2 (en) 2017-02-21
US20140275196A1 (en) 2014-09-18
EP2827862A1 (en) 2015-01-28
US20220323584A1 (en) 2022-10-13
US20200368355A1 (en) 2020-11-26
JP2022141895A (ja) 2022-09-29
JP7133070B2 (ja) 2022-09-07
US20160144034A1 (en) 2016-05-26
JP6570601B2 (ja) 2019-09-04
CA2867295C (en) 2020-08-11
EP4360621A3 (en) 2024-05-22
PL2827862T3 (pl) 2024-05-06
JP2021178846A (ja) 2021-11-18
HUE064884T2 (hu) 2024-04-28
US20180000938A1 (en) 2018-01-04
US20160296622A1 (en) 2016-10-13
HRP20240056T1 (hr) 2024-03-29
US20180369383A1 (en) 2018-12-27
US9597399B2 (en) 2017-03-21
CN104302291A (zh) 2015-01-21
US20200282057A1 (en) 2020-09-10
US9144568B1 (en) 2015-09-29
US20210106686A1 (en) 2021-04-15
EP4360621A2 (en) 2024-05-01
US9034908B2 (en) 2015-05-19
US9597397B2 (en) 2017-03-21
US20190192659A1 (en) 2019-06-27
JP2022130629A (ja) 2022-09-06
US10052385B2 (en) 2018-08-21
US20160000759A1 (en) 2016-01-07
US20220265829A1 (en) 2022-08-25
SI2827862T1 (sl) 2024-03-29
US20180185488A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
JP7133070B2 (ja) ベンダムスチンの製剤
JP6738376B2 (ja) 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
US20230241218A1 (en) Formulations of bendamustine
HK40109505A (en) Formulations of bendamustine
US20260000767A1 (en) Formulations of bendamustine

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170508

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171122

R150 Certificate of patent or registration of utility model

Ref document number: 6250628

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250